assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Active site-targeting, potent and selective aldose reductase (AR) inhibitor with >100-fold selectivity over aldehyde reductase (AHR).
Fidarestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Fidarestat has recently been shown to prevent inflammatory signals (TNF-α, LPS) that cause cancer (colon, breast, prostate and lung), metastasis, asthma, and other inflammatory diseases, as well as being useful for treatment of diabetic neuropathy.
Fidarestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Fidarestat has recently been shown to prevent inflammatory signals (TNF-α, LPS) that cause cancer (colon, breast, prostate and lung), metastasis, asthma, and other inflammatory diseases, as well as being useful for treatment of diabetic neuropathy.
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持